7 hours ago
1
Monty Rakusen
Novartis (NYSE:NVS) to acquire Tourmaline Bio (NASDAQ:TRML) for $48.00 per share in cash, or a total equity value of approximately $1.4 billion.
The transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular
English (US) ·